An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain
Completed
UCB Pharma
Phase 2
2001-05-01
This trial is the follow-on trial to a preceeding open-label trial which included patients
with chronic refractory neuropathic pain. It is conducted at one site in the United Kingdom
and the patient enrollment is completed. The patients had successfully completed the above
mentioned trial and, in the investigator's opinion, would benefit from long-term
administration of Lacosamide. After a 1-week run-in phase the patients were uptitrated to
their optimal dose and then continued into the maintenance phase. Different pain qualities
are assessed by a patient's diary.
Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.
Completed
UCB Pharma
Phase 2
2006-10-01
This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to
placebo in reducing the signs and symptoms of fibromyalgia syndrome.
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
Completed
UCB Pharma
Phase 2
2007-02-01
The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by
mouth, twice a day for up to 18 weeks to prevent migraines.
Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee
Terminated
UCB Pharma
Phase 2
2007-03-01
The purpose of this trial is to evaluate the effectiveness, safety and tolerability of
lacosamide (LCM) 400mg/day in treating the signs and symptoms of osteoarthritis of the knee.
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
Completed
UCB BIOSCIENCES, Inc.
Phase 3
2007-08-01
The objective of this historical-controlled trial is to demonstrate the efficacy and safety
of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are
withdrawn from 1 to 2 marketed antiepileptic drugs.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
